You have 9 free searches left this month | for more free features.

Smoldering%20Multiple%20Myeloma

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Smoldering Multiple Myeloma (SMM) Trial (Linvoseltamab)

Not yet recruiting
  • Smoldering Multiple Myeloma (SMM)
  • (no location specified)
Jul 13, 2023

Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) Trial (Linvoseltamab)

Not yet recruiting
  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
  • Smoldering Multiple Myeloma (SMM)
  • (no location specified)
Nov 17, 2023

Smoldering Multiple Myeloma Trial (Selinexor)

Not yet recruiting
  • Smoldering Multiple Myeloma
  • (no location specified)
Oct 27, 2022

Smoldering Multiple Myeloma Trial in Rochester (Denosumab)

Active, not recruiting
  • Smoldering Multiple Myeloma
  • Rochester, New York
    University of Rochester
Oct 3, 2022

Multiple Myeloma, Smoldering Multiple Myeloma Trial in Oslo (TG01)

Not yet recruiting
  • Multiple Myeloma
  • Smoldering Multiple Myeloma
  • TG01
  • Oslo, Norway
    Oslo Myeloma Center
May 2, 2023

Multiple Myeloma, Smoldering Multiple Myeloma Trial in Boston (Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine

Not yet recruiting
  • Multiple Myeloma
  • Smoldering Multiple Myeloma
  • Ciltacabtagene Autoleucel
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 2, 2023

High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma Trial in Boston (Teclistamab, Lenalidomide,

Recruiting
  • High-risk Smoldering Multiple Myeloma
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Aug 11, 2022

Multiple Myeloma Trial run by the National Cancer Institute (NCI) (Dexamethasone, Carfilzomib, Daratumumab)

Recruiting
  • Multiple Myeloma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Multiple Myeloma Trial in Miami (Teclistamab, Talquetamab, Daratumumab SC)

Not yet recruiting
  • Multiple Myeloma
  • Miami, Florida
    University of Miami
Oct 20, 2023

Multiple Myeloma, High Risk Smoldering Multiple Myeloma Trial in United States (Ixazomib (MLN9708), Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • High Risk Smoldering Multiple Myeloma
  • Basking Ridge, New Jersey
  • +5 more
Nov 15, 2022

Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma Trial in Cleveland (Multiple

Not yet recruiting
  • Multiple Myeloma
  • +2 more
  • Multiple Myeloma M-Protein Analysis
  • Multiple Myeloma Knowledge Questionnaires
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Apr 26, 2023

Multiple Myeloma, Smoldering Trial in United States (Omega-3, Curcumin, Probiotic)

Recruiting
  • Multiple Myeloma, Smoldering
  • Omega-3
  • +3 more
  • Basking Ridge, New Jersey
  • +6 more
Oct 1, 2023

Smoldering Multiple Myeloma Trial in Boston (Ixazomib, Lenalidomide, Dexamethasone)

Active, not recruiting
  • Smoldering Multiple Myeloma
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 15, 2022

Prostate Cancer, Multiple Myeloma, Smoldering Multiple Myeloma (SMM) Trial in Rochester (Curcumin plus Piperine)

Recruiting
  • Prostate Cancer
  • +3 more
  • Curcumin plus Piperine
  • Rochester, New York
    University of Rochester
Jun 17, 2022

Myeloma Trial in Houston (Belantamab mafodotin)

Recruiting
  • Myeloma
  • Belantamab mafodotin
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma Trial in United States (Metformin XR, Placebo)

Recruiting
  • Monoclonal Gammopathy of Undetermined Significance
  • Smoldering Multiple Myeloma
  • Metformin XR
  • Placebo
  • Boston, Massachusetts
  • +6 more
Oct 3, 2022

Smoldering Plasma Cell Myeloma Trial in Houston (Laboratory Biomarker Analysis, Pembrolizumab)

Active, not recruiting
  • Smoldering Plasma Cell Myeloma
  • Laboratory Biomarker Analysis
  • Pembrolizumab
  • Houston, Texas
    M D Anderson Cancer Center
Mar 23, 2022

Quality of Life in Asymptomatic Monoclonal Gammopathies

Recruiting
  • Monoclonal Gammopathy of Undetermined Significance
  • Smoldering Plasma Cell Myeloma
  • Quality-of-Life Assessment
  • Questionnaire Administration
  • Houston, Texas
    M D Anderson Cancer Center
Oct 25, 2022

Smoldering Multiple Myeloma Trial in United States (Carfilzomib, Lenalidomide, Daratumumab)

Active, not recruiting
  • Smoldering Multiple Myeloma
  • Tampa, Florida
  • +9 more
Jul 8, 2022

Two Biologically and Clinically Distinct Entities: Progressive

Recruiting
  • Multiple Myeloma
  • +2 more
    • Miami, Florida
      University of Miami Hospitals
    Jun 7, 2022

    Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance Trial in United States (Whole Foods Plant-based Diet, Algae

    Recruiting
    • Multiple Myeloma
    • Monoclonal Gammopathy of Undetermined Significance
    • Whole Foods Plant-based Diet
    • +2 more
    • Basking Ridge, New Jersey
    • +6 more
    Jan 3, 2023

    Smoldering Multiple Myeloma Trial in Boston (Nivolumab, Lenalidomide, Dexamethasone)

    Suspended
    • Smoldering Multiple Myeloma
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    Jan 4, 2022

    Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma Trial in United States (Plant based meals)

    Recruiting
    • Monoclonal Gammopathy of Undetermined Significance
    • Smoldering Multiple Myeloma
    • Plant based meals
    • Basking Ridge, New Jersey
    • +6 more
    Apr 11, 2022

    Questionnaire and Tissue Banking For Multiple Myeloma,

    Active, not recruiting
    • Multiple Myeloma
    • +3 more
      • Boston, Massachusetts
        Dana-Farber Cancer Institute
      Mar 15, 2022

      High-risk Smoldering Multiple Myeloma, Multiple Myeloma Trial in Boston (Daratumumab, Bortezomib, Lenalidomide)

      Recruiting
      • High-risk Smoldering Multiple Myeloma
      • Multiple Myeloma
      • Boston, Massachusetts
      • +1 more
      Oct 18, 2021